Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Zagozdzon, Agnieszka M ^a   O'Leary, Patrick ^a   Callanan, John J ^a   Crown, John ^b   Gallagher, William M ^a   Zagozdzon, Radoslaw ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Bioluminescence; Breast cancer; In vivo imaging; Luciferase; Mmtv promoter; Transgenic mice

Indexed keywords

LUCIFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MONITORING; BIOLUMINESCENCE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CONTROLLED STUDY; EMBRYO; EX VIVO STUDY; FEMALE; HOMOZYGOSITY; IN VIVO STUDY; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN EXPRESSION; TISSUE SECTION; TRANSGENIC MOUSE;

ANIMALS; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; FEMALE; FOUNDER EFFECT; HOMOZYGOTE; HUMANS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; TRANSGENES;

EID: 84861535100     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-209     Document Type: Article

References (29)

1. Taneja P, Frazier DP, Kendig RD, Maglic D, Sugiyama T, Kai F, Taneja NK, Inoue K. MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Rev Mol Diagn 2009, 9(5):423-440. 10.1586/erm.09.31, 2759974, 19580428.
2. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007, 7(5):389-397. 10.1038/nrc2127, 17446858.
3. Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, Ferrer-Ramon C, Luque-Garcia A, Garcia-Castillo J, Parra-Palau JL, Scaltriti M, et al. A naturally occurring HER2 carboxy-terminalfragment promotes mammary tumor growth and metastasis. Mol Cell Biol 2009, 29(12):3319-3331. 10.1128/MCB.01803-08, 2698729, 19364815.
4. Kwong KY, Hung MC. A novel splice variant of HER2 with increased transformation activity. Mol Carcinog 1998, 23(2):62-68. 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O, 9808159.
5. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994, 369(6482):669-671. 10.1038/369669a0, 8208295.
6. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 1987, 49(4):465-475. 10.1016/0092-8674(87)90449-1, 3032456.
7. Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984, 38(3):627-637. 10.1016/0092-8674(84)90257-5, 6488314.
8. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992, 12(3):954-961. 369527, 1312220.
9. Lynn KD, Udugamasooriya DG, Roland CL, Castrillon DH, Kodadek TJ, Brekken RA. GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. BMC Cancer 2010, 10:397. 10.1186/1471-2407-10-397, 2920882, 20673348.
10. Roland CL, Lynn KD, Toombs JE, Dineen SP, Udugamasooriya DG, Brekken RA. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One 2009, 4(11):e7669. 10.1371/journal.pone.0007669, 2766251, 19888452.
11. O'Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT. Bioluminescent imaging: a critical tool in pre-clinical oncology research. J Pathol 2010, 220(3):317-327.
12. Penet MF, Mikhaylova M, Li C, Krishnamachary B, Glunde K, Pathak AP, Bhujwalla ZM. Applications of molecular MRI and optical imaging in cancer. Future Med Chem 2010, 2(6):975-988. 10.4155/fmc.10.25, 2902367, 20634999.
13. van der Meel R, Gallagher WM, Oliveira S, O'Connor AE, Schiffelers RM, Byrne AT. Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. Drug Discov Today 2010, 15(3-4):102-114.
14. Paguio A, Stecha P, Wood KV, Fan F. Improved dual-luciferase reporter assays for nuclear receptors. Current Chem Genomics 2010, 4:43-49.
15. Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, Innocent N, Cardiff RD, Schnall MD, Chodosh LA. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2002, 2(6):451-461. 10.1016/S1535-6108(02)00212-X, 12498714.
16. Marchini C, Gabrielli F, Iezzi M, Zenobi S, Montani M, Pietrella L, Kalogris C, Rossini A, Ciravolo V, Castagnoli L, et al. The human splice variant Delta16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS One 2011, 6(4):e18727. 10.1371/journal.pone.0018727, 3084693, 21559085.
17. Vargo-Gogola T, Heckman BM, Gunther EJ, Chodosh LA, Rosen JM. P190-B Rho GTPase-activating protein overexpression disrupts ductal morphogenesis and induces hyperplastic lesions in the developing mammary gland. Mol Endocrinol 2006, 20(6):1391-1405.
18. Samuelson LC. Transgenic approaches to salivary gland research. Annu Rev Physiol 1996, 58:209-229. 10.1146/annurev.ph.58.030196.001233, 8815792.
19. Ahmed F, Wyckoff J, Lin EY, Wang W, Wang Y, Hennighausen L, Miyazaki J, Jones J, Pollard JW, Condeelis JS, et al. GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice. Cancer Res 2002, 62(24):7166-7169.
20. Zhang N, Fang Z, Contag PR, Purchio AF, West DB. Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse. Blood 2004, 103(2):617-626. 10.1182/blood-2003-06-1820, 14512298.
21. Lyons SK, Meuwissen R, Krimpenfort P, Berns A. The generation of a conditional reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice. Cancer Res 2003, 63(21):7042-7046.
22. Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L, Li M, Furth PA, Hennighausen L. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 1997, 25(21):4323-4330. 10.1093/nar/25.21.4323, 147032, 9336464.
23. Zhang Q, Triplett AA, Harms DW, Lin WC, Creamer BA, Rizzino A, Wagner KU. Temporally and spatially controlled expression of transgenes in embryonic and adult tissues. Trans Res 2010, 19(3):499-509.
24. Safran M, Kim WY, O'Connell F, Flippin L, Gunzler V, Horner JW, Depinho RA, Kaelin WG. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A 2006, 103(1):105-110. 10.1073/pnas.0509459103, 1324998, 16373502.
25. Goldman SJ, Chen E, Taylor R, Zhang S, Petrosky W, Reiss M, Jin S. Use of the ODD-luciferase transgene for the non-invasive imaging of spontaneous tumors in mice. PLoS One 2011, 6(3):e18269. 10.1371/journal.pone.0018269, 3066234, 21479246.
26. Creamer BA, Triplett AA, Wagner KU. Longitudinal analysis of mammogenesis using a novel tetracycline-inducible mouse model and in vivo imaging. Genesis 2009, 47(4):234-245. 10.1002/dvg.20480, 2775060, 19208431.
27. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007, 7(9):659-672. 10.1038/nrc2193, 17721431.
28. Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A, Deng CX. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999, 22(1):37-43. 10.1038/8743, 10319859.
29. Kuo C, Coquoz O, Troy TL, Xu H, Rice BW. Three-dimensional reconstruction of in vivo bioluminescent sources based on multispectral imaging. J Biomed Opt 2007, 12(2):024007. 10.1117/1.2717898, 17477722.